BusinessNews brief
Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, reinforcing the biotech pipeline for the fall window.
Sources and context
ReutersSource headline and summary supplied via NewsData.io. First collected by NewsJaws on 2026-09-19. This is an automated news brief, not original NewsJaws reporting. Dates reflect the source publication. Feed delays may apply.